{
  "paper": {
    "doi": null,
    "pmcid": "PMC12780394",
    "title": "Global bibliometric analysis of pleural mesothelioma biomarkers (2002\u20132024): trends and emerging frontiers",
    "authors": [
      "Not specified"
    ],
    "journal": "Not specified",
    "year": 2024,
    "study_type": "bibliometric analysis",
    "eco_type": null
  },
  "extraction_provenance": {
    "extraction_pipeline": {
      "name": "medlit_pass1_extract",
      "version": "0.1.0",
      "git_commit": "777544707e2808fd01d9cb8fbe5dc1d74b29532b",
      "git_commit_short": "7775447",
      "git_branch": "main",
      "git_dirty": true,
      "repo_url": "https://github.com/org/medlit"
    },
    "models": {
      "llm": {
        "name": "claude-sonnet-4-20250514",
        "version": ""
      }
    },
    "prompt": {
      "version": "v1",
      "template": "medlit_extraction_v1",
      "checksum": "sha256:5bdf447f3cfe242d"
    },
    "execution": {
      "timestamp": "2026-02-27T16:13:57.101837Z",
      "hostname": "unknown",
      "python_version": "3.13.3",
      "duration_seconds": 47.91
    },
    "entity_resolution": null,
    "model_info": null
  },
  "entities": [
    {
      "id": "pleural_mesothelioma",
      "class": "Disease",
      "name": "pleural mesothelioma",
      "synonyms": [
        "PM",
        "malignant pleural mesothelioma"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "mesothelin",
      "class": "Protein",
      "name": "mesothelin",
      "synonyms": [
        "SMRP",
        "soluble mesothelin-related peptide"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "osteopontin",
      "class": "Protein",
      "name": "osteopontin",
      "synonyms": [
        "OPN",
        "secreted phosphoprotein 1",
        "SPP1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "pd_l1",
      "class": "Protein",
      "name": "programmed cell death ligand-1",
      "synonyms": [
        "PD-L1",
        "soluble PD-L1",
        "sPD-L1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "mir_182_5p",
      "class": "Gene",
      "name": "miR-182-5p",
      "synonyms": [
        "microRNA-182-5p"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "let_7b",
      "class": "Gene",
      "name": "let-7b",
      "synonyms": [
        "let-7b microRNA"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "bap1",
      "class": "Protein",
      "name": "BRCA1-associated protein 1",
      "synonyms": [
        "BAP1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "foxo1",
      "class": "Protein",
      "name": "forkhead box O1",
      "synonyms": [
        "FOXO1"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "foxo3",
      "class": "Protein",
      "name": "forkhead box O3",
      "synonyms": [
        "FOXO3"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "kl_6",
      "class": "Protein",
      "name": "KL-6",
      "synonyms": [
        "Krebs von den Lungen-6"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "nivolumab",
      "class": "Drug",
      "name": "nivolumab",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "ipilimumab",
      "class": "Drug",
      "name": "ipilimumab",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "pembrolizumab",
      "class": "Drug",
      "name": "pembrolizumab",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "pemetrexed",
      "class": "Drug",
      "name": "pemetrexed",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "checkmate_743",
      "class": "ClinicalTrial",
      "name": "CheckMate 743",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "keynote_028",
      "class": "ClinicalTrial",
      "name": "KEYNOTE-028",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "chest_pain",
      "class": "Symptom",
      "name": "chest pain",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "pleural_effusion",
      "class": "Symptom",
      "name": "pleural effusion",
      "synonyms": [],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "car_t_therapy",
      "class": "Procedure",
      "name": "chimeric antigen receptor T-cell therapy",
      "synonyms": [
        "CAR-T therapy"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    },
    {
      "id": "immune_checkpoint_inhibitors",
      "class": "Drug",
      "name": "immune checkpoint inhibitors",
      "synonyms": [
        "ICIs"
      ],
      "symbol": null,
      "brand_names": [],
      "source": "extracted",
      "canonical_id": null,
      "umls_id": null,
      "hgnc_id": null,
      "rxnorm_id": null,
      "loinc_code": null,
      "uniprot_id": null
    }
  ],
  "evidence_entities": [
    {
      "id": "paper_1:introduction:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "intro_1",
      "text": "Pleural mesothelioma (PM), an aggressive and rare malignancy arising from pleural mesothelial cells, accounts for only 0.3% of all cancer cases and remains largely incurable",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:introduction:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "intro_2",
      "text": "PM exhibits a high fatality rate, with a 5-year survival probability below 10% and a median survival duration of merely 9 to 12 months",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:introduction:3:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "intro_3",
      "text": "The predominant risk factor for PM is asbestos exposure, with approximately 80% of cases linked to prior asbestos contact",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:1:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "disc_1",
      "text": "Mesothelin is one of the widely studied biomarkers of PM, which is expressed at low levels in normal cells and undetectable in normal tissues, but is abundantly expressed in malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other cancers",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:2:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "disc_2",
      "text": "SMRP are the only biomarkers for PM approved by the U.S. Food and Drug Administration (FDA)",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:3:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "disc_3",
      "text": "miR-182-5p's oncogenic function was first identified in melanoma, where the miRNA promotes tumor migration and invasion by inhibiting the activity of the forkhead box O3 (FOXO3) transcription factor",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:4:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "disc_4",
      "text": "The forkhead box O1 (FOXO1) transcription factor has been identified as a target of miR-182 and miR-183 regulation in PM cells",
      "confidence": 0.95,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    },
    {
      "id": "paper_1:discussion:5:llm",
      "class": "Evidence",
      "entity_id": null,
      "paper_id": "paper_1",
      "text_span_id": "disc_5",
      "text": "In the non-epithelial subpopulation, sPD-L1 levels were slightly higher, suggesting that sPD-L1 levels may be involved in the poor prognosis of PM tissue types",
      "confidence": 0.9,
      "extraction_method": "llm",
      "study_type": "bibliometric analysis",
      "eco_type": null,
      "source": "extracted"
    }
  ],
  "relationships": [
    {
      "subject": "pleural_mesothelioma",
      "predicate": "ASSOCIATED_WITH",
      "object": "asbestos exposure",
      "evidence_ids": [
        "paper_1:introduction:3:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "percentage": "80%"
      },
      "section": "introduction",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "pleural_mesothelioma",
      "predicate": "INDICATES",
      "object": "chest_pain",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.85,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "pleural_mesothelioma",
      "predicate": "INDICATES",
      "object": "pleural_effusion",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.85,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "mesothelin",
      "predicate": "INDICATES",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:1:llm",
        "paper_1:discussion:2:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "fda_approved": true
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "osteopontin",
      "predicate": "INDICATES",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "pd_l1",
      "predicate": "INDICATES",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:5:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "mir_182_5p",
      "predicate": "INCREASES_RISK",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:3:llm",
        "paper_1:discussion:4:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "mechanism": "inhibits FOXO3"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "nivolumab",
      "predicate": "TREATS",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "combination": "with ipilimumab"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "ipilimumab",
      "predicate": "TREATS",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {
        "combination": "with nivolumab"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "pembrolizumab",
      "predicate": "TREATS",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "mir_182_5p",
      "predicate": "ASSOCIATED_WITH",
      "object": "foxo1",
      "evidence_ids": [
        "paper_1:discussion:4:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "relationship": "regulatory target"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "mir_182_5p",
      "predicate": "ASSOCIATED_WITH",
      "object": "foxo3",
      "evidence_ids": [
        "paper_1:discussion:3:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.9,
      "properties": {
        "relationship": "inhibits activity"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "car_t_therapy",
      "predicate": "TREATS",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.85,
      "properties": {
        "target": "mesothelin"
      },
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    },
    {
      "subject": "immune_checkpoint_inhibitors",
      "predicate": "TREATS",
      "object": "pleural_mesothelioma",
      "evidence_ids": [
        "paper_1:discussion:1:llm"
      ],
      "source_papers": [
        "paper_1"
      ],
      "confidence": 0.95,
      "properties": {},
      "section": "discussion",
      "asserted_by": "llm",
      "resolution": null,
      "note": null
    }
  ],
  "notes": [
    "This bibliometric analysis covers 662 publications on pleural mesothelioma biomarkers from 2002-2024",
    "The study identifies emerging research hotspots including immunotherapy and epigenetics",
    "SMRP (soluble mesothelin-related peptide) is currently the only FDA-approved biomarker for pleural mesothelioma",
    "The analysis reveals a shift from traditional research approaches to precision medicine centered on immunotherapy"
  ]
}